Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7313745 | 0.87 | KMT2A (0.54) | KMT2AKDM4EMEN1CYP1A2CYP2C19 | |
| SCHEMBL4165132 | 0.84 | RAB9A (0.74) | RAB9AROCK2KMT2AKDM4EALDH1A1 | |
| SCHEMBL5529987 | 0.83 | RAB9A (0.60) | RAB9AROCK2KMT2AKDM4EMEN1 | |
| SCHEMBL7364681 | 0.83 | RAB9A (0.72) | RAB9AROCK2KDM4EALDH1A1TDP1 | |
| SCHEMBL5518570 | 0.83 | RAB9A (0.56) | RAB9AROCK2KMT2AKDM4EMEN1 | |
| SCHEMBL10969027 | 0.83 | KDM4E (0.62) | RAB9AKMT2AKDM4EMEN1CYP1A2 | |
| SCHEMBL7312518 | 0.82 | RAB9A (0.59) | RAB9AKDM4EALDH1A1TDP1DRD1 | |
| Hydrochloric Acid SCHEMBL6831889 | 0.82 | RAB9A (0.59) | RAB9ALMNAROCK2KDM4EALDH1A1 | |
| SCHEMBL742272 | 0.82 | RAB9A (0.75) | RAB9AROCK2KMT2AKDM4EALDH1A1 | |
| SCHEMBL17242135 | 0.81 | RAB9A (0.61) | RAB9AROCK2KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | RAB9A 902/4885LMNA 2932/4885ROCK2 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.